dactinomycin has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| El Gendy, MA; El-Kadi, AO; Korashy, HM; Maayah, ZH | 1 |
1 review(s) available for dactinomycin and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for dactinomycin and su 11248
| Article | Year |
|---|---|
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP1A1; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Humans; Indoles; Ligands; MCF-7 Cells; Protein-Tyrosine Kinases; Pyrroles; Receptors, Aryl Hydrocarbon; Resveratrol; RNA, Messenger; Stilbenes; Sunitinib; Transcriptional Activation | 2013 |